日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Dose Selection for DuoBody®-CD40x4-1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data

利用临床前和临床数据，采用 mPBPK/RO 模型选择 DuoBody®-CD40x4-1BB (GEN1042/BNT312) 的剂量

期刊:Clinical Pharmacology & Therapeutics
影响因子:5.5
doi:10.1002/cpt.3677
Bajaj, Gaurav; Shchelokov, Dmitry; Demin, Oleg Jr; Adams, Homer C 3rd; Feng, Yan; Gibiansky, Leonid; van der Lee, Saskia; Johri, Anandhi; Belete, Merzu; Muik, Alexander; Panorchan, Porntula; Türeci, Özlem; Sahin, Uğur; Ahmadi, Tahamtan; Gupta, Manish; Demin, Oleg; Thalhauser, Craig
T细胞
CD4
CD40
发表日期：2025
文献求助 收藏

Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial

伊伐卡托治疗4至12个月以下患有囊性纤维化且携带门控突变的婴儿：一项分为两部分的3期临床试验结果

期刊:American Journal of Respiratory and Critical Care Medicine
影响因子:19.4
doi:10.1164/rccm.202008-3177OC
Davies, Jane C; Wainwright, Claire E; Sawicki, Gregory S; Higgins, Mark N; Campbell, Daniel; Harris, Christopher; Panorchan, Paul; Haseltine, Eric; Tian, Simon; Rosenfeld, Margaret
发表日期：2021
文献求助 收藏

Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor

基于生理的囊性纤维化患者从单药或双药治疗过渡到三联疗法（依来卡托/替扎卡托/伊伐卡托）的CFTR调节药代动力学模型

期刊:Pulmonary Therapy
影响因子:3
doi:10.1007/s41030-020-00124-7
Tsai, Alice; Wu, Shu-Pei; Haseltine, Eric; Kumar, Sanjeev; Moskowitz, Samuel M; Panorchan, Paul; Shah, Kushal
CFTR
发表日期：2020
文献求助 收藏

Correction to: Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor

更正：基于生理的囊性纤维化患者从单药或双药治疗过渡到三联疗法（依来卡托/替扎卡托/伊伐卡托）时CFTR调节的药代动力学模型

期刊:Pulmonary Therapy
影响因子:3
doi:10.1007/s41030-020-00128-3
Tsai, Alice; Wu, Shu-Pei; Haseltine, Eric; Kumar, Sanjeev; Moskowitz, Samuel M; Panorchan, Paul; Shah, Kushal
CFTR
发表日期：2020
文献求助 收藏

Strategies for preserving residual renal function in peritoneal dialysis patients

腹膜透析患者保留残余肾功能的策略

期刊:Clinical Kidney Journal
影响因子:4.6
doi:10.1093/ckj/sfu140
Nongnuch, Arkom; Assanatham, Montira; Panorchan, Kwanpeemai; Davenport, Andrew
发表日期：2015
文献求助 收藏

Incidence and Predictors of Zinc Deficiency in Stable Peritoneal Dialysis Patients

稳定期腹膜透析患者锌缺乏的发生率及预测因素

期刊:Peritoneal Dialysis International
影响因子:3.7
doi:10.3747/pdi.2014.00134
Panorchan, Kwanpeemai; Davenport, Andrew
发表日期：2015
文献求助 收藏

Liver-to-plasma vaniprevir (MK-7009) concentration ratios in HCV-infected patients

丙型肝炎病毒感染患者肝脏与血浆中瓦尼普韦（MK-7009）浓度比值

期刊:Antiviral Therapy
影响因子:2.3
doi:10.3851/IMP2958
Wright, D Hamish; Caro, Luzelena; Cerra, Michael; Panorchan, Paul; Du, Lihong; Anderson, Melanie; Potthoff, Andrej; Nachbar, Robert B; Wagner, John; Manns, Michael P; Talal, Andrew H
炎症/感染
肝炎
微生物学
发表日期：2015
文献求助 收藏

Diagnostic and prognostic role of peritoneal CA 125 in peritoneal dialysis patients presenting with acute peritonitis

腹膜CA 125在出现急性腹膜炎的腹膜透析患者中的诊断和预后作用

期刊:BMC Nephrology
影响因子:2.4
doi:10.1186/1471-2369-15-149
Panorchan, Kwanpeemai; Davenport, Andrew
发表日期：2014
文献求助 收藏

Nuclear lamin A/C deficiency induces defects in cell mechanics, polarization, and migration

核纤层蛋白A/C缺乏会导致细胞力学、极化和迁移缺陷

期刊:Biophysical Journal
影响因子:3.1
doi:10.1529/biophysj.106.102426
Lee, Jerry S H; Hale, Christopher M; Panorchan, Porntula; Khatau, Shyam B; George, Jerry P; Tseng, Yiider; Stewart, Colin L; Hodzic, Didier; Wirtz, Denis
细胞生物学
发表日期：2007
文献求助 收藏

Single-molecule analysis of human immunodeficiency virus type 1 gp120-receptor interactions in living cells

利用单分子分析方法研究活细胞中人类免疫缺陷病毒1型gp120与受体的相互作用

期刊:Journal of Virology
影响因子:3.8
doi:10.1128/JVI.79.23.14748-14755.2005
Chang, Melissa I; Panorchan, Porntula; Dobrowsky, Terrence M; Tseng, Yiider; Wirtz, Denis
HIV
信号转导
微生物学
细胞生物学
免疫/内分泌
发表日期：2005
文献求助 收藏